TBS6b
TBS6b is a potent and selective ACKR3 molecular glue degrader. TBS6b degrades ACKR3 via the ubiquitin-proteasome pathway. TBS6b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion. TBS6b is relevant to hepatocellular carcinoma (HCC) research.
For research use only. We do not sell to patients.
- Formula: C29H28N2O6
- Molecular Weight:500.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
ACKR3 |
TBS6b (0-4 μM; 48 h; HCCLM3 and HepG2 cells) reduces cell proliferation, migration, and invasion[1].
TBS6b (0-4 μM; 48 h; HCCLM3 and HepG2 cells) downregulates the expression of proliferation and mesenchymal markers (PCNA, N-cadherin, and Vimentin), while upregulating the epithelial marker E-cadherin in a dose-dependent fashion. TBS6b selectively inhibits ACKR3 protein expression without altering its mRNA levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCCLM3 and HepG2 cells
-
Concentration:0 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:48 h
-
Result:Significantly reduced cell proliferation in a dose-dependent manner.
-
Cell Line:HCCLM3 and HepG2 cells
-
Concentration:0 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:48 h
-
Result:Significantly reduced cell migration in a dose-dependent manner.
-
Cell Line:HCCLM3 and HepG2 cells
-
Concentration:0 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:48 h
-
Result:Significantly reduced cell invasion in a dose-dependent manner.
-
Cell Line:HCCLM3 and HepG2 cells
-
Concentration:0 μM, 1 μM, 2 μM, 4 μM
-
Incubation Time:48 h
-
Result:Selectively inhibits ACKR3 protein expression without altering its mRNA levels.
TBS6b (5 mg/kg; IP; every other day; 4 weeks) reduces metastasis, and shows no significant changes in liver or kidney tissues in a mouse lung metastasis model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Balb/c-Foxn1nu mice (4-5 weeks) were subcutaneously injected with 1 × 107 cells/mL sh-NC and sh-ACKR3 (derived from HCCLM3) and NC and ACKR3 (derived from HepG2) cells[1].
-
Dosage:5 mg/kg
-
Administration:IP; every other day; 14 days
-
Result:Suppressed tumor growth and metastasis without inducing significant toxicity, as evidenced by stable body weight, normal organ histology, and unchanged serum levels of ALT, AST, BUN, and CRE.
-
Animal Model:Male Balb/c-Foxn1nu mice (4-5 weeks) were intravenously injected with 1 × 107 cells/mL sh-NC and sh-ACKR3 (derived from HCCLM3) and NC and ACKR3 (derived from HepG2) cells[1].
-
Dosage:5 mg/kg
-
Administration:IP; every other day; 4 weeks
-
Result:Reduced metastasis. Decreased levels of Ki67, N-cadherin, and Vimentin, and increased E-cadherin in HCCLM3 cells, with no marked difference between combined and single-agent treatments.
Chemical Information
-
Molecular Weight 500.54
-
Formula C29H28N2O6
-
SMILES
COC1=C(C(OC)=C2C(C=C(OC2=C1)C3=CC=C(C=C3)OCCCN4C(C)=NC5=C4C=CC=C5)=O)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TBS6b Related Classifications
HY-179035 Related Classifications
Powered by Bioz